Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Rheumatology (Oxford) ; 39(10): 1132-8, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11035135

RESUMO

OBJECTIVE: To assess whether vasopressin V1a receptor blockade reduces the abnormal vasoactive response to cold in patients suffering from Raynaud's phenomenon (RP). METHODS: SR 49059, an orally active, non-peptidic vasopressin V1a receptor antagonist, was given orally (300 mg once daily) to 20 patients with RP in a single-centre, double-blind, placebo-controlled, randomized cross-over study with two 7-day periods of treatment separated by 21 days of washout. Bilateral finger systolic blood pressure and skin temperature were assessed before and after immersion of the hand in cold water for 3 min (15 degrees C) during the screening phase and three times (before and 2 and 4 h after drug intake) on days 1 and 7 of each of the two treatment periods. Recovery of digital pressure and skin temperature was measured 0, 10, 20 and 32 min after the end of the cold immersion test. RESULTS: SR 49059 significantly attenuated the cold-induced fall in systolic pressure by 14.5% (95% confidence interval 0-29; P = 0.045) on the most affected hand on day 7 compared with placebo. Temperature recovery after the end of the cold test showed a trend to enhancement 2 and 4 h after SR 49059 on day 7 (P = 0.060 and P = 0.062 respectively). The beneficial effects on finger pressure and temperature recovery were obtained without changes in supine blood pressure or in heart rate. CONCLUSION: SR 49059 given orally once a day for 7 days to patients with RP showed favourable effects compared with placebo on finger systolic pressure and temperature recovery after cold immersion, without inducing side-effects.


Assuntos
Antagonistas de Hormônios/uso terapêutico , Indóis/uso terapêutico , Pirrolidinas/uso terapêutico , Doença de Raynaud/tratamento farmacológico , Adulto , Idoso , Antagonistas dos Receptores de Hormônios Antidiuréticos , Pressão Sanguínea/efeitos dos fármacos , Temperatura Baixa , Estudos Cross-Over , Método Duplo-Cego , Feminino , Dedos/fisiopatologia , Humanos , Imersão , Masculino , Pessoa de Meia-Idade , Doença de Raynaud/fisiopatologia , Temperatura Cutânea/efeitos dos fármacos
2.
Anticancer Res ; 19(2B): 1445-50, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10365121

RESUMO

BACKGROUND: Growth of pancreatic carcinoma cells is stimulated by cholecystokinin (CCK) and neurotensin (NT). Prostatic carcinoma cells can secrete neurotensin. The CCK gene has been described in thyroid medullary carcinomas (MCT). METHODS: Serum CCK and NT were measured by RIAs during monitoring of 19 pancreas tumours, 10 prostate adenocarcinomas and 10 thyroid medullary cancers (MCT). RESULTS: No correlations were found between CCK and NT in the three tumour types, nor with CA 19.9, PSA, CEA or calcitonin. In pancreas adenocarcinomas (n = 12), initial median CCK was > 8pg/ml (non significant differences between stages T, N or M). Median NT was > 80 pg/ml in all but M0 and stage I-II cases, and significantly higher in M1 and stages IV (P = 0.002). Non significant differences were found for CCK and NT according to clinical stages. In prostate cancers, median CCK was significantly more elevated after relapse (P = 0.040). Median NT was significantly more elevated in disease-free patients (P = 0.04). In MCT, CCK and NT were not related to clinical stages. CONCLUSION: In pancreas and prostate cancers serum CCK may follow tumour load and disease progression. NT was lower in progressive disease. The contribution of these peptides in human tumour growth, since they may have therapeutic implication, warrants further investigation.


Assuntos
Adenocarcinoma/sangue , Biomarcadores Tumorais/sangue , Carcinoma Medular/sangue , Colecistocinina/sangue , Neurotensina/sangue , Neoplasias Pancreáticas/sangue , Neoplasias da Próstata/sangue , Neoplasias da Glândula Tireoide/sangue , Adenocarcinoma/patologia , Idoso , Antígeno CA-19-9/sangue , Calcitonina/sangue , Antígeno Carcinoembrionário/sangue , Carcinoma Medular/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias Pancreáticas/patologia , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/patologia , Estudos Retrospectivos , Neoplasias da Glândula Tireoide/patologia
3.
Ann Trop Paediatr ; 12(1): 41-6, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1376586

RESUMO

An energy-dense supplementary food, together with nutrition education, was given to a group of moderately malnourished children aged 6-12 months in a poor slum community of urban Bangladesh. An age- and sex-matched control group received only nutrition education. Both groups were followed monthly with respect to weight gain and morbidity. The purpose of the study was to assess the differential impact of a targeted supplementary feeding programme with nutrition education and a nutrition education programme alone on monthly weight gain during 6 months. During the 1st 3 months of the intervention, the monthly weight gain of the supplemented children was 205 g vs 159 g in the control children (p less than 0.05). In the following 3 months, differences in weight gain were no more significant. Several possible explanations for this transient impact are discussed. It is suggested that nutrition education in the control group may have been responsible for the limited difference between the two groups, but seasonal and epidemiological factors may also have played a part.


Assuntos
Alimentos Fortificados , Fenômenos Fisiológicos da Nutrição do Lactente , Bangladesh , Feminino , Seguimentos , Educação em Saúde , Humanos , Lactente , Masculino , Áreas de Pobreza , Avaliação de Programas e Projetos de Saúde , População Urbana , Aumento de Peso
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...